Aimspro clinical trials successfully treat several conditions

  • 11 years ago
Gillian Jordan has been taking Aimspro for 3 years. She has adhesive arachnoiditis, a neuropathic inflammatory disease, which left her incontinent, in pain and in a wheelchair. After 3 years of treatment, her symptoms have lessened and she is now able walk with the aid of a cane.

Aimspro is currently in phase 2 clinical trials and Dr Brian Youl, Clinical Director at Daval International, suggests the compound has the capacity to repair damaged nerve fibres in a variety of conditions.

Another Aimspro patient, Ngozi Chiejina, suffers from juvenile chronic arthritis and lupus. She explains how the treatment has given her renewed independence.

For more information about Aimspro visit: http://www.davalinternational.com/